<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="165410">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944554</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00019900</org_study_id>
    <nct_id>NCT00944554</nct_id>
  </id_info>
  <brief_title>Relapse Prevention With Varenicline</brief_title>
  <acronym>0815</acronym>
  <official_title>Relapse Prevention With Varenicline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if varenicline (Chantix®), currently used as a smoking
      cessation aid, will decrease the likelihood of relapse to smoking following a programmed
      lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing
      effects of smoking and will delay or prevent relapse compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators plan to use an experimental model of a lapse, in which
      volunteers smoke two cigarettes after a brief period of (12-24 hours). The goals of this
      study are to assess the impact of varenicline on the subjective and reinforcing effects of
      cigarettes, as well as the latency to resume smoking (relapse) following the lapse exposure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volunteers to relapse and time to relapse</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective and reinforcing effects of cigarettes</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Recurrence</condition>
  <condition>Smoking Cessation</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group given placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group given varenicline dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline and placebo given twice a day or five weeks.</description>
    <arm_group_label>Varenicline</arm_group_label>
    <other_name>Varenicline (Chantix®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Varenicline and placebo given twice a day or five weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years old

          -  Reports smoking at least 10 cigarettes per day AND provides a urine sample that tests
             positive for nicotine metabolites at intake

          -  Contemplating a smoking cessation attempt in the near future

          -  Willing to engage in a practice quit attempt during which they will be asked to smoke
             on one occasion

          -  Able to give informed consent

        Exclusion Criteria:

          -  Currently meets DSM-IV criteria for depression, bi-polar disorder, or schizophrenia

          -  History of attempted suicide or expresses any current suicidal ideation

          -  Pregnant, breast feeding, or planning to become pregnant within the next 3 months

          -  Reports desire for immediate treatment of tobacco/nicotine dependence

          -  Severe impairment of renal function indicated by GFR less than 30 ml/min calculated
             using the Cockcroft and Gault prediction method (plasma creatinine adjusted by
             weight, gender, and age)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxine L Stitzer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <lastchanged_date>May 31, 2012</lastchanged_date>
  <firstreceived_date>July 21, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Maxine L. Stitzer/Professor</name_title>
    <organization>Johns Hopkins University</organization>
  </responsible_party>
  <keyword>Relapse</keyword>
  <keyword>Smoking Cessation</keyword>
  <keyword>Substance Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
